Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.38 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | TYMP | P19971 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7266107 | 0.86 | ADORA1 (0.47) | CARM1ENPP1TRDMT1ADORA1TYMP | |
| SCHEMBL6835045 | 0.86 | ADORA1 (0.45) | P2RX3P2RX4P2RX2CARM1ENPP1 | |
| SCHEMBL6238364 | 0.86 | P2RX3 (0.37) | P2RX3P2RX4P2RX2CARM1ENPP1 | |
| SCHEMBL6229383 | 0.86 | POLB (0.38) | P2RX3P2RX4P2RX2CARM1ENPP1 | |
| SCHEMBL7074034 | 0.84 | ST6GAL1 (0.38) | — | |
| SCHEMBL6834851 | 0.82 | P2RX3 (0.38) | P2RX3P2RX4P2RX2CARM1ENPP1 | |
| SCHEMBL6231869 | 0.82 | TAAR1 (0.41) | TYMP | |
| SCHEMBL10690523 | 0.80 | ADORA3 (0.50) | P2RX3P2RX4P2RX2CARM1TRDMT1 | |
| SCHEMBL6834950 | 0.79 | P2RX3 (0.37) | P2RX3P2RX4P2RX2CARM1ENPP1 | |
| SCHEMBL6835157 | 0.79 | P2RX3 (0.37) | P2RX3P2RX4P2RX2CARM1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | GRIFFEY RICHARD H (US) | 2003-01-16 | — | — | US | disclosed |
| US-6458941-B1 | RECOVERED FROM WASTE PRODUCTS OF OLIGONUCLEOTIDE BIOSYNTHESIS | ISIS PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013864-A1 | Method for the synthesis of nucleotide of oligonucleotide phosphoramidites | NUDT1, MTAP, PHOSPHO1 | P2RX3 633/4885P2RX4 399/4885P2RX2 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.